[{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"GHRF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"GHRF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"GHRF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"GHRF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"GHRF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Marathon Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Hormone","year":"2022","type":"Financing","leadProduct":"Tesamorelin Acetate","moa":"GHRF","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Theratechnologies \/ Marathon Asset Management","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Marathon Asset Management"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"World Orphan Drug Alliance","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Hormone","year":"2023","type":"Agreement","leadProduct":"Tesamorelin Acetate","moa":"GHRF","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Theratechnologies \/ World Orphan Drug Alliance","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ World Orphan Drug Alliance"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ibalizumab","moa":"CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Italian Medicines Agency","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Ibalizumab","moa":"CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Theratechnologies \/ Italian Medicines Agency","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Italian Medicines Agency"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CANADA","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"GHRF","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"GHRF","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"GHRF","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"GHRF","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"GHRF","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Piramal Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2021","type":"Agreement","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Piramal Pharma Solutions","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Piramal Pharma Solutions"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ PPD","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ PPD"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CANADA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"GHRF","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CANADA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"GHRF","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"TH1904","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Windtree Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Windtree Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Windtree Therapeutics"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Theratechnologies

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          World Vaccine Conference
                          Not Confirmed
                          World Vaccine Conference
                          Not Confirmed

                          Details : Egrifta WR (tesamorelin acetate) is a growth hormone releasing factor (GRF) analog used to reduce excessive abdominal fat in HIV patients who have developed lipodystrophy.

                          Product Name : Egrifta WR

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          March 25, 2025

                          Lead Product(s) : Tesamorelin Acetate

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          World Vaccine Conference
                          Not Confirmed
                          World Vaccine Conference
                          Not Confirmed

                          Details : Egrifta (tesamorelin) is a growth hormone releasing factor (GRF) analog used to reduce excessive abdominal fat in HIV patients who have developed lipodystrophy.

                          Product Name : Egrifta

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          December 10, 2024

                          Lead Product(s) : Tesamorelin Acetate

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          World Vaccine Conference
                          Not Confirmed
                          World Vaccine Conference
                          Not Confirmed

                          Details : TH1902 (sudocetaxel zendusortide) is a peptide-drug conjugate that targets SORT1. It is being developed for treatment of high-grade serous ovarian cancer, including high-grade fallopian tube cancer.

                          Product Name : TH1902

                          Product Type : Peptide-drug Conjugate

                          Upfront Cash : Inapplicable

                          December 09, 2024

                          Lead Product(s) : Sudocetaxel Zendusortide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          World Vaccine Conference
                          Not Confirmed
                          World Vaccine Conference
                          Not Confirmed

                          Details : Egrifta (tesamorelin) is a growth hormone releasing factor (GRF) analog used to reduce excessive abdominal fat in HIV patients who have developed lipodystrophy.

                          Product Name : Egrifta

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          November 26, 2024

                          Lead Product(s) : Tesamorelin Acetate

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          World Vaccine Conference
                          Not Confirmed
                          World Vaccine Conference
                          Not Confirmed

                          Details : TH1902 is an investigational, first-in-class PDC that targets SORT1, being developed for high-grade serous ovarian, fallopian tube, or endometrioid cancer.

                          Product Name : TH1902

                          Product Type : Peptide-drug Conjugate

                          Upfront Cash : Inapplicable

                          March 21, 2024

                          Lead Product(s) : Sudocetaxel Zendusortide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          World Vaccine Conference
                          Not Confirmed
                          World Vaccine Conference
                          Not Confirmed

                          Details : Trogarzo (ibalizumab-uiyk) is a long-acting, CD4-directed, post-attachment HIV-1 inhibitor. It is being evaluated for the treatment of adults with multidrug-resistant HIV-1 infection.

                          Product Name : Trogarzo

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          February 27, 2024

                          Lead Product(s) : Ibalizumab

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          World Vaccine Conference
                          Not Confirmed
                          World Vaccine Conference
                          Not Confirmed

                          Details : TH1902 is an investigational, first-in-class PDC that targets SORT1, being developed for high-grade serous ovarian, fallopian tube, or endometrioid cancer.

                          Product Name : TH1902

                          Product Type : Peptide-drug Conjugate

                          Upfront Cash : Inapplicable

                          February 15, 2024

                          Lead Product(s) : Sudocetaxel Zendusortide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          World Vaccine Conference
                          Not Confirmed
                          World Vaccine Conference
                          Not Confirmed

                          Details : Trogarzo (ibalizumab-uiyk) is a long-acting, CD4-directed HIV-1 inhibitor. Its intramuscular dose regimen is in phase 3 development for treating HIV-1 infection.

                          Product Name : Trogarzo

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          February 01, 2024

                          Lead Product(s) : Ibalizumab

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          World Vaccine Conference
                          Not Confirmed
                          World Vaccine Conference
                          Not Confirmed

                          Details : Egrifta (tesamorelin) is a growth hormone releasing factor (GRF) analog used to reduce excessive abdominal fat in HIV patients who have developed lipodystrophy.

                          Product Name : Egrifta

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          January 24, 2024

                          Lead Product(s) : Tesamorelin Acetate

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          World Vaccine Conference
                          Not Confirmed
                          World Vaccine Conference
                          Not Confirmed

                          Details : Egrifta (tesamorelin) is a growth hormone releasing factor (GRF) analog used to reduce excessive abdominal fat in HIV patients who have developed lipodystrophy.

                          Product Name : Egrifta

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          January 23, 2024

                          Lead Product(s) : Tesamorelin Acetate

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank